

A practical guide for providers on helping patients find Itraconazole. Five actionable steps, alternative agents, and workflow tips for your practice.
It's a scenario that's become all too common: you prescribe Itraconazole for a patient with onychomycosis, blastomycosis, histoplasmosis, or another fungal infection, and within hours your office gets a call — the pharmacy doesn't have it.
Itraconazole availability has been inconsistent in recent years, particularly for the oral solution formulation. As a prescriber, you're in a unique position to help your patients navigate these challenges before they become treatment disruptions.
This guide outlines the current availability landscape, explains why patients are struggling, and gives you five practical steps to improve fill rates.
Here's the formulation-by-formulation picture in 2026:
For the latest supply data and a patient-facing overview, see our Itraconazole shortage update for 2026.
Understanding the barriers helps you anticipate and address them:
Itraconazole API (active pharmaceutical ingredient) is sourced from a limited number of global suppliers. Any disruption — quality issues, regulatory holds, shipping delays — creates downstream shortages that affect multiple finished-product manufacturers simultaneously.
Most retail pharmacies use just-in-time inventory. They don't maintain buffer stock of medications with lower prescription volume. Itraconazole, while important, isn't dispensed at the volume of medications like Lisinopril or Metformin, so many pharmacies keep minimal or zero stock on hand.
Patients may not realize that capsules and oral solution are different products with different availability. A pharmacy may have capsules but not the solution (or vice versa), leading to fill failures if the prescription specifies a formulation that's out of stock.
Prior authorization requirements for brand-name versions (Sporanox, Tolsura) can delay access by days. Step therapy requirements may force patients to try and fail on generic capsules before accessing Tolsura, even when the SUBA formulation is clinically preferable.
Use Medfinder for Providers to verify which pharmacies near your patient currently have Itraconazole in stock. Sending a prescription to a pharmacy that actually has the medication eliminates the most common failure point.
This takes about 30 seconds and can be integrated into your prescribing workflow — have your MA or nurse check availability while you finalize the encounter note.
Consider these approaches to maximize fill probability:
Build relationships with pharmacies that consistently stock antifungals:
Cost is a treatable barrier. At the point of prescribing:
Know your second-line agents for each indication so you can switch quickly if Itraconazole can't be sourced:
For a detailed comparison, see our provider briefing on the Itraconazole shortage.
Create a simple protocol for your care team when a patient reports they can't fill Itraconazole:
At the time of prescribing, tell patients:
Add a note or alert to your Itraconazole order set flagging potential availability issues and listing your preferred alternative agents. This ensures any provider in your practice can handle the situation consistently.
Itraconazole access challenges are a systems problem, but individual providers can make a meaningful difference. By checking availability before prescribing, maintaining pharmacy relationships, addressing cost proactively, and having backup plans ready, you can protect your patients from treatment disruptions.
Start using Medfinder for Providers to check Itraconazole availability in real time and streamline your prescribing workflow.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.